Last updated: July 26, 2026
SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (D.N.J. 3:18-cv-02213-FLW-TJB): Litigation Summary, Claims, and Generic-Entry Risk Analysis
Executive summary: The case is a Hatch-Waxman patent infringement action in the District of New Jersey (D.N.J.) brought by Sun Pharma Global FZE against Lupin Limited, docketed as 3:18-cv-02213-FLW-TJB. The available prompt does not include the asserted patent numbers, Orange Book reference product, drug strength/formulation(s) at issue, claim construction outcomes, dispositive motions, settlement terms, or final judgment. Without those case-specific details, a complete, accurate litigation summary and infringement/validity analysis cannot be produced.
What patents were asserted in SUN PHARMA GLOBAL FZE v. LUPIN LIMITED 3:18-cv-02213-FLW-TJB?
Answer (based on provided information): Not specified in the supplied input.
Which specific Orange Book-listed patents were the focus?
Not specified in the supplied input.
Were method-of-use, formulation, or manufacturing patents asserted?
Not specified in the supplied input.
How many asserted patents were in the complaint?
Not specified in the supplied input.
What claims were litigated (infringement, invalidity, and unenforceability) in 3:18-cv-02213-FLW-TJB?
Answer (based on provided information): Not specified in the supplied input.
Was the dispute tied to Paragraph IV certifications or another FDA regulatory mechanism?
Not specified in the supplied input.
What defenses were raised by Lupin (noninfringement, invalidity, or §271(e)(2) scope)?
Not specified in the supplied input.
Did the court address inequitable conduct or other litigation conduct issues?
Not specified in the supplied input.
When did the parties file key motions in SUN PHARMA GLOBAL FZE v. LUPIN LIMITED (3:18-cv-02213-FLW-TJB)?
Answer (based on provided information): Not specified in the supplied input.
What was the claim construction (Markman) schedule and outcome?
Not specified in the supplied input.
Were there summary judgment rulings?
Not specified in the supplied input.
Were preliminary injunction or TRO issues raised and decided?
Not specified in the supplied input.
What is the procedural posture of 3:18-cv-02213-FLW-TJB (dismissal, trial, settlement, or final judgment)?
Answer (based on provided information): Not specified in the supplied input.
Did the case end in a settlement agreement?
Not specified in the supplied input.
If settled, did the docket reflect consent judgment, covenant-not-to-sue, or dismissal with prejudice?
Not specified in the supplied input.
Is there an appeal to the Federal Circuit?
Not specified in the supplied input.
How does SUN PHARMA GLOBAL FZE v. LUPIN LIMITED affect generic entry timelines for Lupin’s ANDA product?
Answer (based on provided information): Not specified in the supplied input.
Did the litigation delay approval, launch, or both?
Not specified in the supplied input.
Which exclusivity and patent expirations controlled the risk window (for the Orange Book reference listed drug)?
Not specified in the supplied input.
Did the court’s rulings alter expected launch dates or design-around options?
Not specified in the supplied input.
What generic-entry risks existed for Lupin during the pendency of 3:18-cv-02213-FLW-TJB?
Answer (based on provided information): Not specified in the supplied input.
What infringement theory was alleged (ANDA product, process, or method-of-use)?
Not specified in the supplied input.
What were the technical design-around barriers (formulation/process/label changes)?
Not specified in the supplied input.
What litigation risk bucket dominated (validity vs noninfringement)?
Not specified in the supplied input.
What court decisions in 3:18-cv-02213-FLW-TJB drove outcomes (claim construction, JMOL, or evidentiary rulings)?
Answer (based on provided information): Not specified in the supplied input.
Were there dispositive rulings on patent validity under §102/§103/§112?
Not specified in the supplied input.
Did the court address indefiniteness, enablement, or written description?
Not specified in the supplied input.
Was infringement evaluated via claim charts, expert testimony, or summary judgment?
Not specified in the supplied input.
How does this SUN v. Lupin dispute compare with similar Sun Pharma v. generic patent cases in the D.N.J.?
Answer (based on provided information): Not specified in the supplied input.
Common themes across Sun Pharma patent enforcement in D.N.J.
Not specified in the supplied input.
Differences by therapeutic area or patent type
Not specified in the supplied input.
Key Takeaways
The prompt provides only the case caption and docket number (3:18-cv-02213-FLW-TJB) and does not include asserted patents, product identity, claims, procedural milestones, orders, or outcome. A litigation summary and analysis that is complete and accurate cannot be generated from the supplied information.
FAQs
- What patents did Sun Pharma Global FZE assert against Lupin Limited in 3:18-cv-02213-FLW-TJB?
- What was the Orange Book reference product and which FDA submission triggered the Hatch-Waxman case?
- Did the court issue claim construction or dispositive rulings in 3:18-cv-02213-FLW-TJB?
- Did the case end by settlement, dismissal, or judgment, and what did it mean for Lupin launch timing?
- What design-around strategies or label changes were relevant to the asserted claims?
References
- United States District Court for the District of New Jersey, case docket: Sun Pharma Global FZE v. Lupin Limited, 3:18-cv-02213-FLW-TJB.
